Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$20.03 USD
+0.03 (0.15%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $20.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.03 USD
+0.03 (0.15%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $20.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
Here's Why Fresenius (FMS) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Fresenius (FMS) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
by Zacks Equity Research
Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
by Zacks Equity Research
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company???s transformational plans continue to benefit its operating income.
Can These 3 Medical Device Stocks Hit Earnings This Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Fresenius (FMS) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Implied Volatility Surging for Fresenius Medical (FMS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Fresenius Medical (FMS) stock based on the movements in the options market lately.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Indrajit Bandyopadhyay
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
by Zacks Equity Research
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Will These 5 Medical Device Stocks Beat This Earnings Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Analyzing How You Should Play Cigna (CI) Ahead of Q1 Earnings
by Zacks Equity Research
The first-quarter results of Cigna (CI) are likely to reflect expanding commercial middle market memberships and growth in Cigna Healthcare profits.
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
by Indrajit Bandyopadhyay
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.